Bo Yuan

Bo Yuan

Auto-generated profile, based on publicly available information

Bo Yuan

Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2020 in Genetics in Medicine
Verified
Journal Article
Closed access
BYBo Yuan
Bo Yuan
LWLei Wang
Lei Wang
PLPengfei Liu
Pengfei Liu
CSChad Shaw
Chad Shaw
HDHongzheng Dai
Hongzheng Dai
WBWeimin Bi
Weimin Bi

25 April 2024 in NEJM AI
Verified
Journal Article
Closed access
DMDongxue Mao
Dongxue Mao
CLChaozhong Liu
Chaozhong Liu
LWLinhua Wang
Linhua Wang
RARami Ai-Ouran
Rami Ai-Ouran
CDCole Deisseroth
Cole Deisseroth
ZLZhandong Liu
Zhandong Liu
Diagnosing genetic disorders requires extensive manual curation and interpretation of candidate variants, a labor-intensive task even for trained geneticists. Although artificial intelligence (AI) shows promise in aiding these diagnoses, existing AI tools have only achieved moderate success for primary diagnosis. AI-MARRVEL (AIM) uses a random-forest machine-learning classifier trained on over 3.5 million variants from thousands of diagnosed cases. AIM additionally incorporates expert-engineered features into training to recapitulate the intricate decision-making processes in molecular diagnosis. The online version of AIM is available at https://ai.marrvel.org. To evaluate AIM, we benchmarked it with diagnosed patients from three independent cohorts. AIM improved the rate of accurate genetic diagnosis, doubling the number of solved cases as compared with benchmarked methods, across three distinct real-world cohorts. To better identify diagnosable cases from the unsolved pools accumulated over time, we designed a confidence metric on which AIM achieved a precision rate of 98% and identified 57% of diagnosable cases out of a collection of 871 cases. Furthermore, AIM’s performance improved after being fine-tuned for targeted settings including recessive disorders and trio analysis. Finally, AIM demonstrated potential for novel disease gene discovery by correctly predicting two newly reported disease genes from the Undiagnosed Diseases Network. AIM achieved superior accuracy compared with existing methods for genetic diagnosis. We anticipate that this tool may aid in primary diagnosis, reanalysis of unsolved cases, and the discovery of novel disease genes. (Funded by the NIH Common Fund and others.)

28 January 2021 in Blood
Verified
Journal Article
Open access
PDF file
FSFrancesco Saettini
Francesco Saettini
Cecilia Poli-HarloweCecilia Poli-Harlowe
Cecilia Poli-Harlowe
JVJaime Vengoechea
Jaime Vengoechea
SBSonia Bonanomi
Sonia Bonanomi
JOJulio C. Orellana
Julio C. Orellana
ABAndrea Biondi
Andrea Biondi
Agammaglobulinemia is the most profound primary antibody deficiency that can occur due to an early termination of B-cell development. We here investigated 3 novel patients, including the first known adult, from unrelated families with agammaglobulinemia, recurrent infections, and hypertrophic cardiomyopathy (HCM). Two of them also presented with intermittent or severe chronic neutropenia. We identified homozygous or compound-heterozygous variants in the gene for folliculin interacting protein 1 (FNIP1), leading to loss of the FNIP1 protein. B-cell metabolism, including mitochondrial numbers and activity and phosphatidylinositol 3-kinase/AKT pathway, was impaired. These defects recapitulated the Fnip1−/− animal model. Moreover, we identified either uniparental disomy or copy-number variants (CNVs) in 2 patients, expanding the variant spectrum of this novel inborn error of immunity. The results indicate that FNIP1 deficiency can be caused by complex genetic mechanisms and support the clinical utility of exome sequencing and CNV analysis in patients with broad phenotypes, including agammaglobulinemia and HCM. FNIP1 deficiency is a novel inborn error of immunity characterized by early and severe B-cell development defect, agammaglobulinemia, variable neutropenia, and HCM. Our findings elucidate a functional and relevant role of FNIP1 in B-cell development and metabolism and potentially neutrophil activity.

7 December 2021 in npj Genomic Medicine
Verified
Journal Article
Open access
PDF file
VOVolkan Okur
Volkan Okur
ZCZefu Chen
Zefu Chen
LVLiesbeth Vossaert
Liesbeth Vossaert
SPSandra Peacock
Sandra Peacock
JRJill Rosenfeld
Jill Rosenfeld
BYBo Yuan
Bo Yuan
The histone H3 variant H3.3, encoded by two genes H3-3A and H3-3B, can replace canonical isoforms H3.1 and H3.2. H3.3 is important in chromatin compaction, early embryonic development, and lineage commitment. The role of H3.3 in somatic cancers has been studied extensively, but its association with a congenital disorder has emerged just recently. Here we report eleven de novo missense variants and one de novo stop-loss variant in H3-3A (n = 6) and H3-3B (n = 6) from Baylor Genetics exome cohort (n = 11) and Matchmaker Exchange (n = 1), of which detailed phenotyping was conducted for 10 individuals (H3-3A = 4 and H3-3B = 6) that showed major phenotypes including global developmental delay, short stature, failure to thrive, dysmorphic facial features, structural brain abnormalities, hypotonia, and visual impairment. Three variant constructs (p.R129H, p.M121I, and p.I52N) showed significant decrease in protein expression, while one variant (p.R41C) accumulated at greater levels than wild-type control. One H3.3 variant construct (p.R129H) was found to have stronger interaction with the chaperone death domain-associated protein 6.

1 February 2022 in Genetics in Medicine
Verified
Journal Article
Closed access
CCChun-An Chen
Chun-An Chen
JLJohn Lattier
John Lattier
WZWenmiao Zhu
Wenmiao Zhu
JRJill Rosenfeld
Jill Rosenfeld
LWLei Wang
Lei Wang
BYBo Yuan
Bo Yuan

27 February 2025 in Journal of Experimental Medicine
Verified
Journal Article
Closed access
NSNoa Simchoni
Noa Simchoni
SKShogo Koide
Shogo Koide
MLMaryel Likhite
Maryel Likhite
YKYoshihiko Kuchitsu
Yoshihiko Kuchitsu
SKSenkottuvelan Kadirvel
Senkottuvelan Kadirvel
ASAnthony K. Shum
Anthony K. Shum
COPA syndrome, an autosomal-dominant inborn error of immunity, is nonpenetrant in ∼20% of individuals, with no known mediators of protection. Recent studies implicate STING in the pathogenesis of COPA syndrome. We show that the common HAQ STING allele mediates complete clinical protection. We sequenced 35 individuals with COPA mutations, 26 affected patients and 9 unaffected carriers, finding HAQ STING co-segregation with clinical nonpenetrance. Exome sequencing identified only the mutations comprising HAQ STING as variants shared by unaffected carriers and absent in patients. Experimentally, we found that HAQ STING acts dominantly to dampen COPA-dependent STING signaling. Expressing HAQ STING in patient cells rescued the molecular phenotype of COPA syndrome. Our study is the first report of a common and well-tolerated allele mediating complete clinical protection from a severe genetic disorder. Our findings redefine the diagnostic criteria for COPA syndrome, expose functional differences among STING alleles with broad scientific and clinical implications, and reveal a potential universal gene therapy approach for patients.